FDA announces scientific conference on CBD use and response differences between sexes and genders

September 22, 2020

The U.S. Food and Drug Administration’s Office of Women’s Health has announced that it will be hosting a public meeting discussing the potential sex (biological) and gender (psychosocial) differences in the consumption of and response to cannabidiol (CBD) and other cannabinoids.

The U.S. Food and Drug Administration’s Office of Women’s Health has announced that it will be hosting a public meeting discussing the potential sex (biological) and gender (psychosocial) differences in the consumption of and response to cannabidiol (CBD) and other cannabinoids. The multidisciplinary scientific conference, titled “CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses,” is designed for the benefit of researchers, educators, clinicians, and patients, alike.

“Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of CBD and other cannabinoids, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation,” states FDA is its announcement.

The conference, which is an outcome of FDA’s ongoing information and data gathering efforts through public docket, will take place on November 19, 2020 from 9 am to 4 pm.